Algert Global’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Algert Global’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,814	Closed	-$607K	–	1352
2022 Q3	$607K	Buy	+9,814	New	+$686K	0.04%	740
2016 Q2	–	Sell	-20,872	Closed	-$346K	–	430
2016 Q1	$346K	Buy	20,872 +7,602	+57%	+$133K	0.13%	262
2015 Q4	$288K	Buy	+13,270	New	+$258K	0.13%	240

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Algert Global's HZNP Position: Q4 2022 in Review

Algert Global sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 9,814 shares — an estimated $607K sold.

Algert Global first reported a position in HZNP in Q4 2015 and held it in 3 quarters. The position peaked at $607K in Q3 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Algert Global reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Algert Global sold 9,814 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $607K.
Algert Global first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 3 quarters.
Algert Global's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $607K in Q3 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.